Prakash Bhuyan MD PhD

Infectious Disease•Philadelphia, PA

Senior Vice President, Clinical Development

Join to View Full Profile

3900 Woodland AveUniversity And Woodland AvenuesPhiladelphia, PA 19104

Education & Training

University of Pennsylvania Health SystemFellowship, Infectious Disease, 2001 - 2003
Emory University School of MedicineResidency, Internal Medicine, 1998 - 2001
University of Texas Southwestern Medical SchoolClass of 1998

Certifications & Licensure

PA State Medical License 2001 - 2026
GA State Medical License 1999 - 2001

Clinical Trials

Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) Start of enrollment: 2006 May 01
Completed
Phase 2
Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED) Start of enrollment: 2006 Sep 01
Completed
Phase 3
A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) Start of enrollment: 2006 Oct 06
Completed
Phase 3
Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED) Start of enrollment: 2006 Nov 01
Completed
Phase 3
A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002) Start of enrollment: 2001 May 01
Completed
Phase 2
A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003) Start of enrollment: 2001 May 01
Completed
Phase 2
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) Start of enrollment: 2017 Aug 31
Completed
Phase 2
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Start of enrollment: 2017 Jun 28
Completed
Phase 3
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Start of enrollment: 2018 May 15
Completed
Phase 2
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions Start of enrollment: 2018 Sep 21
ACTIVE_NOT_RECRUITING
PHASE2
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Start of enrollment: 2019 Feb 28
COMPLETED
PHASE3
Hepatitis B Vaccine in Seniors Start of enrollment: 2000 Mar 29
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

HPLC-MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum.
Alexander Schäfer, Peter Sagelsdorff, Björn Hock, Prakash Bhuyan, Norman Moullan
Analytical and Bioanalytical Chemistry. 2024-08-01
3 citations
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 M...
Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem
Infectious Diseases and Therapy. 2024-01-01
6 citations
Cervical High-Grade Squamous Intraepithelial Lesion Burden and Standard of Care Treatment Effectiveness and Safety in the United States, 2008-2018: The EACH-WOMAN Proj...
Katherine C Hughes, Timothy A Herring, Jennifer N Song, Robert V Gately, Lindsey M Przybyl
Journal of Lower Genital Tract Disease. 2023-04-01

Press Mentions

INOVIO to Present at Upcoming Investor Conferences in MarchMarch 2nd, 2021
Inovio Pharmaceuticals Inc (NASDAQ: INO) Q1 2020 Earnings Call TranscriptMay 11th, 2020
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-Associated Vulvar DysplasiaMarch 30th, 2020
Join now to see all